Ticagrelor In Coronary microvascular dysfunction (TIC) Program: Anti-anginal Efficacy in Primary Coronary Microvascular Disorders.

Trial Profile

Ticagrelor In Coronary microvascular dysfunction (TIC) Program: Anti-anginal Efficacy in Primary Coronary Microvascular Disorders.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs Ticagrelor (Primary)
  • Indications Angina pectoris
  • Focus Therapeutic Use
  • Acronyms TIC-2
  • Sponsors AstraZeneca
  • Most Recent Events

    • 10 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 22 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top